Lucerastat Market Summary

Key Factors Driving Lucerastat Growth

1. Potential to address an unmet need across Fabry disease genotypes

Fabry disease is caused by deficient alpha-galactosidase A activity, leading to accumulation of glycosphingolipids such as globotriaosylceramide (Gb3). Lucerastat reduces the production of these substrates rather than replacing the deficient enzyme. Because its mechanism does not depend on a specific GLA mutation, it could potentially serve patients regardless of mutation type, including those who are not eligible for mutation-specific treatment. However, broader clinical use remains a development goal, not an established benefit or approved indication.

2. Oral administration could improve treatment convenience

Lucerastat is administered orally at a studied dose of 1,000 mg twice daily, offering a potential alternative to intravenous enzyme replacement therapy (ERT), which requires recurring infusions. If approved, an oral option could reduce infusion-related logistical burdens for some patients and potentially expand treatment choice. Actual uptake would depend on comparative efficacy, tolerability, eligibility, reimbursement and how it performs against existing Fabry therapies.

3. Biomarker reductions support continued development

In the Phase III MODIFY study, 118 adults across 14 countries were randomized to lucerastat or placebo. At six months, lucerastat produced a significantly greater reduction in plasma Gb3 than placebo: the least-squares mean difference was −873.53 ng/mL. Urinary Gb3 also declined in the lucerastat group. These pharmacodynamic findings support the drug’s biological activity, although biomarker changes alone do not establish improved symptoms or long-term clinical outcomes.

4. Emerging evidence of a potential kidney-protective effect

Renal disease is a major driver of long-term complications in Fabry disease, making kidney-function preservation a potentially important differentiator. In an exploratory open-label extension analysis involving 93 participants, the estimated glomerular filtration rate (eGFR) slope changed from −3.50 to −1.48 mL/min/1.73 m² per year when comparing pre-randomization data with the period after lucerastat treatment. The analysis was not a randomized comparison of these slopes, so the finding requires confirmation. Nevertheless, it helped motivate a new kidney-focused development strategy.

5. Long-term tolerability may support chronic treatment

Fabry disease generally requires lifelong management, making sustained tolerability an important factor in treatment selection. In the open-label extension of MODIFY, 107 patients entered long-term follow-up, with some participants receiving lucerastat for more than six years. Idorsia reported that the longer-term data supported its established safety and tolerability profile, with no treatment-related serious adverse events reported in the company’s 2026 update. Continued monitoring and the results of the new trials will be important to establish the long-term benefit-risk profile.

Lucerastat Recent Developments

In February 2026, Idorsia announced a registration-focused program agreed with the US FDA. It comprises a pivotal kidney-biopsy study involving approximately 16 adult men with classic Fabry disease, designed to assess changes in renal Gb3 burden after 18 months, and a renal-function comparative study involving approximately 74 adults, comparing Lucerastat with established ERTs. The company indicated that the program could support a regulatory filing as early as 2029, depending on study results and regulatory requirements.

“Lucerastat Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Lucerastat for potential indication like Fabry’s disease in the 7MM. A detailed picture of Lucerastat’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Lucerastat for potential indications. The Lucerastat market report provides insights about Lucerastat’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Lucerastat performance, future market assessments inclusive of the Lucerastat market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Lucerastat sales forecasts, along with factors driving its market.

Lucerastat Drug Summary

Lucerastat is an investigational, orally administered small-molecule drug developed by Idorsia Pharmaceuticals for the treatment of Fabry disease, a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene that lead to deficient or dysfunctional alpha-galactosidase A (α-Gal A) enzyme activity and the accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in various tissues. Lucerastat acts as an inhibitor of glucosylceramide synthase, an enzyme involved in glycosphingolipid production, thereby reducing the synthesis of substrates that contribute to disease progression. This substrate reduction therapy is designed to work independently of α-Gal A activity and GLA mutation type, potentially offering a treatment option for a broader Fabry disease population than mutation-specific oral chaperone therapies. Its oral administration may also provide a convenient alternative to intravenous enzyme replacement therapy. In the Phase III MODIFY study, lucerastat demonstrated substantial reductions in plasma Gb3 levels and other disease-associated biomarkers; however, it did not meet the primary endpoint of reducing neuropathic pain compared with placebo over six months. Results from the long-term open-label extension, published in Nature Communications in January 2026, reported sustained biomarker reductions and encouraging observations regarding the rate of kidney-function decline, particularly among patients with impaired renal function. The report provides Lucerastat’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Lucerastat Market Report

The report provides insights into:

• A comprehensive product overview including the Lucerastat MoA, description, dosage and administration, research and development activities in potential indication like Fabry’s disease.
• Elaborated details on Lucerastat regulatory milestones and other development activities have been provided in Lucerastat market report.
• The report also highlights Lucerastat‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Lucerastat market report also covers the patents information, generic entry and impact on cost cut.
• The Lucerastat market report contains current and forecasted Lucerastat sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Lucerastat market report also features the SWOT analysis with analyst views for Lucerastat in potential indications.

Methodology

The Lucerastat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lucerastat Analytical Perspective by DelveInsight

• In-depth Lucerastat Market Assessment

This Lucerastat sales market forecast report provides a detailed market assessment of Lucerastat for potential indication like Fabry’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Lucerastat sales data uptil 2034.

• Lucerastat Clinical Assessment

The Lucerastat market report provides the clinical trials information of Lucerastat for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Lucerastat Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Lucerastat Market Potential & Revenue Forecast

• Projected market size for the Lucerastat and its key indications
• Estimated Lucerastat sales potential (Lucerastat peak sales forecasts)
• Lucerastat Pricing strategies and reimbursement landscape

Lucerastat Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Lucerastat Market positioning compared to existing treatments
• Lucerastat Strengths & weaknesses relative to competitors

Lucerastat Regulatory & Commercial Milestones

• Lucerastat Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Lucerastat Clinical Differentiation

• Lucerastat Efficacy & safety advantages over existing drugs
• Lucerastat Unique selling points

Lucerastat Market Report Highlights

• In the coming years, the Lucerastat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Lucerastat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lucerastat’s dominance.
• Other emerging products for Fabry’s disease are expected to give tough market competition to Lucerastat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lucerastat in potential indications.
• Analyse Lucerastat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Lucerastat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Lucerastat in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Lucerastat? How strong is Lucerastat’s clinical and commercial performance?
• What is Lucerastat’s clinical trial status in each individual indications such as Fabry’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lucerastat Manufacturers?
• What are the key designations that have been granted to Lucerastat for potential indications? How are they going to impact Lucerastat’s penetration in various geographies?
• What is the current and forecasted Lucerastat market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Lucerastat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Lucerastat for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Lucerastat? What is the duration of therapy and what are the geographical variations in cost per patient?